public
health
measur
success
identifi
contain
outbreak
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
concern
remain
possibl
futur
recurr
find
vaccin
viru
therefor
remain
high
prioriti
show
dna
vaccin
encod
spike
glycoprotein
sarscov
induc
cell
neutral
antibodi
respons
well
protect
immun
mous
model
altern
form
analys
dna
immun
express
vector
induc
robust
immun
respons
mediat
cell
well
signific
antibodi
titr
measur
enzymelink
immunosorb
assay
moreov
antibodi
respons
mice
vaccin
express
vector
encod
form
includ
transmembran
domain
elicit
neutral
antibodi
viral
replic
reduc
six
order
magnitud
lung
mice
vaccin
plasmid
dna
express
vector
protect
mediat
humor
tcelldepend
immun
mechan
genebas
vaccin
sarscov
elicit
effect
immun
respons
gener
protect
immun
anim
model
sarscov
emerg
asia
highli
aggress
pathogen
lethal
adult
elderli
although
genet
organ
similar
coronavirus
recent
phylogenet
studi
suggest
may
close
relat
type
ii
coronavirus
previous
describ
coronavirus
usual
induc
lethal
diseas
human
pathogen
domest
anim
speci
well
document
experiment
vaccin
develop
anim
provid
insight
mechan
protect
immun
studi
immun
respons
coronavirus
suggest
cellmedi
humor
immun
contribut
longterm
protect
discov
gene
product
mechan
protect
immun
relev
sarscov
two
set
cdna
encod
sarscov
glycoprotein
prepar
use
modifi
codon
optim
express
minim
recombin
endogen
coronavirus
coronavirus
assembl
compart
endoplasm
reticulum
er
golgi
apparatu
leader
may
direct
er
nativ
leader
sequenc
retain
one
set
vector
fig
replac
anoth
set
leader
sequenc
deriv
gene
express
significantli
alter
leader
sequenc
substitut
data
shown
studi
two
carboxytermin
mutant
one
truncat
cytoplasm
domain
sdcd
anoth
delet
transmembran
cytoplasm
region
sdtm
prepar
express
cdna
mammalian
express
vector
suitabl
human
vaccin
confirm
fig
plasmid
encod
modifi
glycoprotein
analys
abil
elicit
antivir
immun
intramuscular
inject
balbc
mice
inject
sdtm
sdcd
express
vector
induc
substanti
immun
respons
mark
increas
observ
number
sarscov
sspecif
tcell
immun
respons
fig
measur
intracellular
cytokin
stain
interferong
ifng
tumour
necrosi
factora
tnfa
addit
substanti
sarscov
sspecif
cellular
immun
detect
level
least
sevenfold
background
respons
humor
immun
initi
assess
use
enzymelink
immunosorb
assay
elisa
lectincaptur
sdtm
protein
express
cell
see
method
substanti
endpoint
dilut
antibodi
titr
observ
group
rang
fig
left
panel
analys
abil
glycoprotein
plasmid
elicit
neutral
antibodi
respons
pseudotyp
assay
perform
anim
immun
sarscov
sdcd
express
vector
induc
substanti
neutral
antibodi
titr
rang
unlik
vector
control
fig
middl
panel
express
vector
transmembran
domain
delet
sdtm
also
induc
neutral
antibodi
titr
lower
vector
partial
cytoplasm
domain
delet
induc
optim
respons
fig
right
panel
similar
neutral
observ
complet
cytoplasm
domain
remov
data
shown
suggest
synthesi
glycoprotein
cell
surfac
without
cytoplasm
domain
requir
respons
may
give
rise
nativ
structur
relev
function
viru
possibl
transmembran
region
help
form
physiolog
form
protein
anchor
protein
membran
preserv
conform
determin
andor
stabil
format
put
trimer
antisera
also
use
sarscov
microneutr
assay
assess
neutral
titr
sarscov
antisera
sdcdvaccin
mice
elicit
potent
neutral
antibodi
respons
fig
right
panel
infect
nonhuman
primat
sarscov
report
evid
pulmonari
patholog
seroconvers
recent
anim
model
may
better
reproduc
sign
time
cours
human
diseas
describ
model
use
ferret
develop
pneumon
increas
viral
replic
observ
murin
model
sarscov
replic
also
describ
recent
intranas
administr
tissu
cultur
infecti
dose
tcid
unit
sarscov
lead
viru
replic
lung
nasal
turbin
within
day
model
afford
us
opportun
examin
immun
protect
viral
replic
respiratori
tract
measur
vaccin
efficaci
balbc
mice
immun
variou
plasmid
dna
encod
protein
challeng
day
final
boost
anim
challeng
intranas
tcid
unit
sarscov
urbani
strain
viral
replic
respiratori
tract
measur
day
later
analysi
potent
immunogen
sar
sdcd
led
fold
reduct
viral
load
lung
compar
control
group
inject
vector
alon
mean
viral
titr
observ
fig
p
although
plasmid
delet
transmembran
domain
elicit
lower
neutral
antibodi
respons
equal
effect
reduc
viral
replic
lung
reduct
viru
titr
nasal
turbin
also
observ
fig
p
case
evid
pro
figur
protect
pulmonari
sarscov
replic
challeng
balbc
mice
follow
dna
vaccin
immun
challeng
perform
mice
describ
previous
viral
replic
mean
log
tcid
per
g
tissu
standard
error
lower
upper
b
respiratori
tract
challeng
sarscov
measur
five
immun
anim
inocul
sdcd
sdtm
empti
plasmid
vector
control
lower
limit
detect
sarscov
replic
tcid
per
g
lung
tcid
per
g
nasal
turbin
nonparametr
twotail
ttest
mannwhitney
use
statist
analysi
logtransform
viru
titr
compar
statist
signific
assign
differ
p
valu
immun
respons
sarscov
dna
vaccin
balbc
mice
intracellular
cytokin
stain
perform
quantifi
percentag
activ
cell
produc
either
ifng
tnfa
respons
stimul
overlap
peptid
pool
left
right
lymphocyt
mice
n
per
group
immun
empti
plasmid
vector
control
mice
n
per
group
immun
indic
plasmid
week
immun
respons
measur
day
final
boost
nonstimul
cell
gave
respons
similar
control
subject
background
level
symbol
indic
respons
individu
anim
median
valu
shown
horizont
bar
b
antibodi
respons
induc
plasmid
dna
vaccin
sarscov
protein
endpoint
dilut
elisa
titr
sarscov
sspecif
antibodi
left
panel
serum
vaccin
anim
collect
day
final
boost
determin
optic
densiti
describ
method
neutral
antisera
mice
immun
relev
sarscov
mutant
insert
control
plasmid
dna
vector
indic
concentr
measur
use
luciferas
assay
pseudotyp
lentivir
vector
middl
panel
reduct
gene
transfer
observ
immun
sera
dosedepend
fashion
twofold
dilut
heatinactiv
sera
test
microneutr
assay
presenc
antibodi
neutral
infect
tcid
sarscov
vero
cell
monolay
use
four
well
per
dilut
plate
right
panel
presenc
viral
cytopath
effect
cpe
read
day
dilut
serum
complet
prevent
cpe
well
calcul
reed
muench
formula
data
present
means
group
nonparametr
twotail
ttest
mannwhitney
use
statist
analysi
relev
p
valu
indic
b
right
panel
letter
natur
ductiv
sarscov
replic
observ
mice
vaccin
plasmid
dna
encod
sdcd
sdtm
defin
mechan
protect
tcell
deplet
specif
monoclon
antibodi
perform
deplet
lung
spleen
confirm
supplementari
fig
deplet
alon
combin
affect
vaccineinduc
immun
fig
find
confirm
role
tcell
immun
analys
adopt
tcell
transfer
donor
immun
cell
unabl
reduc
pulmonari
viral
replic
recipi
anim
fig
p
contrast
passiv
transfer
purifi
igg
immun
control
mice
provid
immun
protect
fig
right
panel
p
compar
observ
dnavaccin
anim
fig
find
indic
immun
cell
control
pulmonari
viru
replic
anim
model
although
remain
possibl
cell
contribut
viral
clearanc
replic
persist
report
dna
vaccin
use
induc
cellular
humor
immun
sarscov
glycoprotein
humor
immun
respons
includ
gener
neutral
antibodi
humor
immun
alon
inhibit
pulmonari
viral
replic
murin
challeng
model
suggest
dna
vaccin
sarscov
glycoprotein
gene
result
protect
immun
sarscov
novel
coronaviru
vaccin
human
coronavirus
success
develop
consider
experi
develop
vaccin
common
veterinari
coronavirus
obtain
anim
coronavirus
felin
infecti
periton
viru
coronaviru
caus
signific
morbid
mortal
domest
anim
vaccin
investig
develop
vaccin
complic
possibl
immun
potenti
diseas
viral
evolut
present
studi
tcell
deplet
immun
igg
passiv
transfer
use
assess
import
humor
respons
protect
sarscov
challeng
result
suggest
antibodi
sarscov
glycoprotein
protect
sarscov
challeng
enhanc
infect
anim
model
cellular
immun
respons
appear
play
limit
role
protect
although
studi
anim
coronavirus
suggest
cellular
humor
immun
contribut
protect
persist
infect
dna
vaccin
use
varieti
anim
model
differ
infecti
diseas
includ
influenza
hiv
ebola
west
nile
virus
review
ref
despit
success
anim
model
approach
recent
use
human
studi
potenti
protect
human
diseas
yet
establish
reason
well
limit
anim
model
sarscov
infect
import
ascertain
immunogen
plasmid
human
respons
suboptim
readili
augment
use
primeboost
combin
inactiv
viral
vaccin
candid
adenovir
poxviru
vector
definit
effect
viral
gene
report
guid
choic
insert
genebas
vaccin
approach
exampl
sdcd
mutant
express
vector
deliveri
system
analysi
alon
variou
combin
although
murin
model
allow
assess
variou
antivir
approach
examin
effect
immun
pulmonari
viru
replic
show
sustain
infect
high
lethal
model
infect
describ
ferret
show
promin
pulmonari
patholog
associ
infect
efficaci
vaccin
pathogen
anim
model
interest
futur
studi
time
known
whether
even
ferret
model
faith
replic
complex
patholog
symptomatolog
human
diseas
necessari
test
potenti
sar
vaccin
candid
immunogen
safeti
efficaci
human
event
futur
outbreak
plasmid
encod
differ
version
sarscov
spike
protein
urbani
strain
genbank
synthes
use
humanpref
codon
previous
describ
protein
express
confirm
western
blot
analysi
serum
recov
patient
provid
w
bellini
immun
mechan
protect
tcell
deplet
adopt
transfer
antibodi
passiv
transfer
monoclon
rat
antimous
use
deplet
cell
sdcd
control
vaccin
mice
n
describ
previous
mice
challeng
sarscov
h
later
viral
replic
lung
measur
describ
fig
data
repres
means
statist
signific
differ
observ
group
deplet
shown
b
lack
protect
sarscov
replic
lung
adopt
tcell
transfer
vaccin
mice
naiv
mous
n
receiv
purifi
cell
donor
mous
confirm
respond
vaccin
immun
nonimmun
mous
control
recipi
mice
challeng
h
adopt
tcell
transfer
viral
titr
lung
measur
describ
fig
statist
signific
differ
two
group
use
nonparametr
mannwhitney
twotail
ttest
p
c
protect
sarscov
replic
lung
passiv
transfer
immun
igg
vaccin
mice
purifi
igg
sdcd
control
vaccin
donor
mice
n
passiv
transfer
recipi
naiv
mice
n
serum
recipi
mice
collect
one
day
challeng
neutral
confirm
use
pseudotyp
lentivir
vector
left
panel
recipi
mice
n
per
group
challeng
h
igg
transfer
tcid
sarscov
sarscov
replic
measur
describ
fig
nonparametr
twotail
ttest
mannwhitney
reveal
statist
signific
differ
p
two
group
right
panel
femal
balbc
mice
week
old
charl
river
lab
immun
mg
plasmid
dna
ml
pb
ph
week
tcell
respons
evalu
use
intracellular
cytokin
flow
cytometri
icc
ifng
tnfa
previous
describ
peptid
pool
mer
overlap
amino
acid
mg
ml
cover
sarscov
spike
protein
cell
fix
permeabil
stain
use
rat
monoclon
antimous
ifng
tnfa
bdpharmingen
ifngand
tnfaposit
cell
cell
popul
analys
program
flowjo
tree
star
inc
mous
antisarss
igg
elisa
titr
measur
use
modifi
lectincaptur
method
describ
previous
twofold
dilut
heatinactiv
sera
test
microneutr
assay
presenc
antibodi
neutral
infect
tcid
sarscov
vero
cell
monolay
use
four
well
per
dilut
plate
presenc
viral
cytopath
effect
cpe
test
day
dilut
serum
complet
prevent
cpe
well
calcul
reed
muench
formula
vaccin
mice
lightli
anaesthet
isofluran
inocul
ml
dilut
viru
tcid
sarscov
urbani
strain
intranas
accord
institut
anim
care
use
guidelin
facil
day
mice
euthan
lung
nasal
turbin
remov
store
end
studi
frozen
tissu
thaw
homogen
lung
nasal
turbin
wv
suspens
leibovitz
medium
invitrogen
viru
titr
determin
vero
cell
monolay
plate
viru
titr
express
tcid
per
g
tissu
lower
limit
detect
infecti
viru
wv
suspens
lung
log
tcid
per
g
nasal
turbin
homogen
respect
deplet
specif
tcell
subset
known
rat
monoclon
antibodi
antimous
antimous
antimous
prepar
describ
previous
provid
l
epstein
fda
administ
intraperiton
mg
ml
pb
h
challeng
deplet
confirm
challeng
supplementari
fig
igg
mice
immun
plasmid
dna
encod
sdcd
immun
insert
control
purifi
sera
use
protein
antibodi
purif
kit
sigma
neutral
activ
confirm
use
mous
pseudotyp
assay
briefli
ml
purifi
igg
approxim
ml
serum
administ
intraven
recipi
naiv
mous
n
per
group
tail
vein
inject
h
challeng
sera
collect
recipi
balbc
mice
h
post
transfer
confirm
neutral
antibodi
titr
recipi
anim
adopt
tcell
transfer
studi
cell
vaccin
immun
nonimmun
control
mice
enrich
use
pan
tcell
isol
kit
miltenyi
biotec
approxim
cell
ml
pb
administ
recipi
naiv
balbc
mous
intraven
tail
vein
h
challeng
four
recipi
mice
per
group
